Background Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. Objective The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase in transaminases whilst taking agomelatine. Method A retrospective pooled analysis of changes in transaminase levels in 9234 patients treated with agomelatine (25 or 50 mg/day; n = 7605) or placebo (n = 1629) from 49 phase II and III studies was undertaken. A significant increase in transaminase levels was defined as an increase to [3 times the upper limit of normal (ULN) ([3 9 ULN). Final causality was determined in a case-bycase review by five academic experts. Results Serum transaminases increased to [3 9 ULN in 1.3 and 2.5 % of patients treated with 25 and 50 mg of agomelatine, respectively, compared with 0.5 % for placebo. The onset of increased transaminases occurred before 12 weeks in 64 % of patients. The median time to recovery (to B2 9 ULN) was 14 days following treatment withdrawal. Liver function tests recovered in 36.1 % of patients despite continuation of agomelatine, suggesting the presence of a liver adaptive mechanism. No cases of acute liver failure or fatal outcome occurred. Patients with elevated transaminases at baseline, secondary to obesity/fatty liver disease, had an equally increased risk of developing further elevations of transaminases with agomelatine and placebo.
Introduction
Agomelatine belongs to a new class of antidepressants: it is a melatonergic agonist (MT 1 and MT 2 receptors) and a serotonergic 2C (5-HT 2C ) antagonist. Binding studies indicate that agomelatine has no effect on monoamine uptake and no affinity for a-and b-adrenergic, histaminergic, cholinergic, dopaminergic or benzodiazepine receptors [1, 2] . Agomelatine has no addictive properties and its abrupt cessation is not associated with any withdrawal symptoms [3] .
Agomelatine was approved by the European Medicines Agency (EMA) in 2009 for treatment of major depressive episodes in adults [1] . The safety of agomelatine was assessed in a large number of phase II and III studies conducted by Servier and its US partner that included more than 14,000 patients. The most frequent adverse events include, by rank of frequency, headache, nausea, dizziness, somnolence, diarrhoea and dry mouth.
Spontaneous reports of an increase in liver transaminases have been reported in agomelatine-treated patients; therefore, a liver monitoring scheme has been recommended by the EMA. Liver function tests should be performed before starting treatment and then after approximately 3 and 6 weeks (end of acute phase), 12 and 24 weeks (end of maintenance phase), and thereafter when clinically indicated. When increasing the dosage, liver function tests should again be performed at the same frequency as when initiating treatment. Any patient who develops increased serum transaminases should have his/ her liver function tests repeated within 48 h. Agomelatine should be discontinued if the increase in transaminase is[3 times the upper limit of normal (ULN) value (3 9 ULN) [1] .
Currently, the EMA and the marketing authorisation holder (MAH) recommend that agomelatine is administered after careful consideration of the benefit-risk in patients with pre-existing liver diseases including fatty liver, obesity, diabetes mellitus, substantial alcohol intake or concomitant use of drugs with hepatotoxic potential. The scheme of liver monitoring and the data supporting the use of such criteria are lacking. Of note, such data are also lacking for the other antidepressants. It is therefore difficult to draw conclusions about the prevalence and severity of the risk factors for antidepressant-induced liver injury.
In this context of monitoring agomelatine-induced liver enzyme increase, we aimed to examine the incidence and characteristics of transaminase increase in patients treated with agomelatine who participated in phase II and III clinical trials.
Methods

Patients
A retrospective pooled analysis of the hepatic safety of agomelatine was assessed in 14,377 patients participating in all phase II and III trials conducted either by Servier or its US partner and completed by the end of 2013. The data came from 35 completed studies in major depressive disorders (n = 12,307) and 14 completed studies for other indications (n = 2070). Among 49 clinical studies, 28 are published [2, , three are submitted for publication and the others were used for the European registration file. All studies were assessed by the EMA. In total, these studies included 7605 patients treated with agomelatine (25-50 mg) and 1629 patients treated with placebo; importantly, this analysis only included patients in whom there was at least one post-baseline transaminase value. In the present analysis, in order to be able to extend our results to marketed doses of agomelatine, we focused our study on patients treated with 25 and 50 mg daily. We therefore excluded patients treated with other antidepressants or non-marketed doses of agomelatine (1, 5, 10 and 100 mg) and patients for whom no information regarding transaminase levels during treatment was available (Fig. 1) . This left 9234 patients treated with agomelatine or placebo for analysis.
For the purpose of this analysis, an increase in transaminase was defined as significant when there was at least one value of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) [3 9 ULN on treatment. The[3 9 ULN increase in transaminase is based on internationally recognised guidance on drug-induced liver injury [31] . Of note, as the transaminase dosage is highly variable among tests, we considered the ULN to be the value that was given by the laboratory for each test.
Assessment of the Causal Relationship
A Liver Safety Committee (LSC) comprised of five academic experts (four hepatologists and one internist) was set up by Servier to monitor liver safety in agomelatine-treated patients. A blinded case-by-case review was performed by the LSC. Experts were asked to classify all of the cases into one of four classes of causality. Levels 1-4 were defined as follows:
1. Probably related to the (study) treatment: this was used when the transaminase increase was clearly suggestive of a drug-related reaction in the absence of known confounding factors or in the presence of confounding factor(s) but was less likely to have caused the event than the study drug. 2. Possibly related to the (study) treatment: compatible with a drug-related reaction, in the absence of known confounding factors or in the presence of confounding factor(s), but not more likely than the study drug to have provoked the event. 3. Unlikely related to study treatment: compatible with a drug-related reaction, but with the presence of one or more confounding factors considered to be more likely than the study drug to have caused the increase in serum transaminase and/or an unusual pattern for a drug-induced reaction. 4. Not related to study treatment: clearly incompatible with a drug-related reaction and/or another cause (e.g. acute hepatitis E) has been identified.
In addition, a fifth causality category (5: unknown) was used only for the first cases occurring before 2008 in placebo-treated patients (n = 7) and reviewed a posteriori in an unblinded condition.
When there was no consensus of causality attributed to a patient, a consensus was achieved during a face-to-face meeting. Further, whenever an expert assigned causality as ''probably related'' (level 1), the case was discussed faceto-face by all experts. In the few cases when consensus was not achieved, the highest level of causality was attributed.
During the initial assessments, and once the drug administered was unblinded, it became apparent that some Time to onset (i.e. the number of days between first intake of agomelatine and the initial significant transaminase abnormality [[3 9 ULN]), outcome and time to recovery were studied in only patients in whom causality was assigned as being ''probably'' or ''possibly'' related to study treatment. Recovery was defined as a return to normal transaminase values or values lower than those observed before the first intake of agomelatine (B2 9 ULN). Patients were considered to be recovering when transaminase decreased to a level \3 9 ULN.
Unadjusted Cox proportional hazard models were used to estimate the effect of each potential risk factor, and the 95 % confidence interval (CI) and associated p value were used in both the agomelatine and placebo groups to confirm the identification of the potential risk factor.
The treatment effect from unadjusted Cox proportional hazard models, the 95 % CI and associated p value were provided by subgroup. The p value for interaction between treatment group and subgroup status was obtained by addition of the interaction term of treatment and subgroup in the model.
Results
Patient Characteristics
Baseline characteristics of the 7605 patients taking agomelatine 25-50 mg/day and the 1629 patients on placebo are reported in Table 1 . At inclusion, there was a higher number of patients with a body mass index [30 kg/ m 2 in the agomelatine group (22.56 %) than in the placebo group (19.52 %). However, the prevalence of high blood pressure and increased AST, c-glutamyltransferase (GGT) and blood glucose was higher in the placebo group (Table 1) . Of note, 7.76 % of patients in the agomelatine group and 8.35 % in the placebo group had a baseline level of ALT higher than the ULN.
There were 139 patients with an increase of transaminase [3 9 ULN. Of these, 131 (1.7 %) patients were taking agomelatine (25 or 50 mg/day) ( Table 2 ) and eight were taking placebo (0.5 %). Of the 131 agomelatine-treated patients with an increase of transaminase [3 9 ULN, 21 cases were assigned as probably related, 65 cases as possibly related, 32 cases as unlikely related and 13 cases were considered unrelated to agomelatine (Fig. 1 ).
Incidence of Increased Transaminases >3 Times the Upper Limit of Normal (3 3 ULN)
The pooled incidence of increased serum transaminases to [3 9 ULN in the 9234 patients analysed was 1.3 and 2.5 % in patients treated with 25 and 50 mg/day of agomelatine, respectively (agomelatine 25 vs. 50 mg/day, p \ 0.001) compared with 0.5 % in placebo-treated patients (agomelatine 25 or 50 mg/day vs. placebo, p \ 0.001).
Twenty patients (0.3 %) taking agomelatine exhibited a marked increase of transaminase [10 9 ULN ( Table 2) ; none of these 20 patients had severe liver injury as defined by the Hy's law criteria. One patient had an increased bilirubin level on agomelatine treatment of 62 lmol/L. However, this case was classified as unlikely to be related to agomelatine due to the chronology of the event and concomitant treatment with itraconazole. No cases of acute liver failure or fatal outcome were reported in the clinical trials.
Analysis of Cases Assigned as ''Possibly'' or ''Probably'' Related
When patients classified as ''possibly'' or ''probably'' related were analysed, the observed frequency of increased transaminases was 0.8 and 1.7 % with agomelatine 25 and 50 mg/day of, respectively, versus none on placebo (agomelatine 25-50 mg/day vs. placebo, p B 0.001) ( Table 2) . Of these patients, a daily dose of agomelatine 50 mg was associated with a higher proportion of patients with a serum transaminase increase [10 9 ULN (0.3 %) than 25 mg/day (0.1 %) (p = 0.075) ( Table 2) . Overall, these data show a dose relationship, with a dose of agomelatine 50 mg/day being associated with a more frequent incidence of serum transaminases increasing to [3 9 ULN. We also assessed the time between the first intake of agomelatine and the first occurrence of a transaminase increase [3 9 ULN. The time to onset of increased serum transaminase [3 9 ULN occurred within the first 12 weeks of treatment in 64 % of patients classified as ''possibly'' or ''probably'' related to agomelatine (Fig. 2a) . In 8.1 % of patients whose transaminase increase was classified as ''possibly'' or ''probably'' related to 
ULN upper limit of normal agomelatine, the onset of the transaminase increase occurred after 24 weeks of treatment.
Outcome and Liver Adaptation
All of the patients with an attributed ''possibly'' or ''probably'' agomelatine-induced transaminase increase for which a follow-up was available (96 % of cases) recovered or were recovering. Three patients classified as ''not recovered'' had a limited period of follow-up; in these patients, no significant change between the maximum and last available transaminase value was noted. The median time to recovery was 14 days following treatment withdrawal.
One striking observation was that many agomelatinetreated patients had an improvement or a normalization of the transaminase level despite continuation of treatment. This phenomenon is called adaptation. Indeed, among the 86 patients in whom the increase in serum transaminase [3 9 ULN was attributed to being possibly or probably related to agomelatine, 31 (36.1 %) demonstrated continued improvement or recovery despite continuation of agomelatine. Recovery of the transaminitis despite continuation of agomelatine was observed at both 25 mg/day (15 patients) and 50 mg/day (16 patients). The time between the first increase in serum transaminases and the first intake of agomelatine also occurred in the majority of patients with adaptation within the first 12 weeks of treatment (Fig. 2b) . The only difference found between patients with and without adaptation was a higher baseline level of GGT in patients without adaptation (Table 3) .
Risk Factors for an Increase in Serum
Transaminases >3 3 ULN The EMA has recommended that patients with pre-existing fatty liver disease (non-alcoholic fatty liver disease [NAFLD]) be treated with agomelatine after careful consideration of the benefit-risk. In this context, we analysed factors that might be associated with significant increases in transaminases of [3 9 ULN. Sex and age were not associated with a risk of transaminase increase (Table 4) . However, the presence of a baseline level of AST, ALT, GGT or triglycerides above the ULN, as well as metabolic syndrome mainly driven by obesity and elevated cholesterol was significantly associated with a higher risk of developing an increase of serum transaminase [3 9 ULN in patients treated with agomelatine. In patients taking placebo, a baseline level higher than the reference range for ALT and GGT was also associated with an increased risk of transaminase elevation [3 9 ULN (Table 4) . However, since the diagnosis of NAFLD relies on a fluctuation of transaminases between 1 and 3 9 ULN, the observation of an increase of transaminase in patients treated with agomelatine may be difficult to interpret. Therefore, in order to test whether NAFLD could be a risk factor of agomelatine-induced transaminase increase, we analysed whether an increased baseline level of transaminase was associated with a higher risk of developing an elevation of transaminase [3 9 ULN. Patients with an increased baseline level of transaminase were more at risk of developing a serum transaminase [3 9 ULN than patients with a normal baseline in both the placebo group (2.55 vs. 0.27 %) and the agomelatine group (3.41 vs. 1.56 %) ( Table 5) .
Patients with normal baseline transaminases had a higher risk of developing an increase of transaminase on agomelatine than on placebo (1.56 vs. 0.27 %; p \ 0.05) ( Table 5 ). However, in patients with elevated baseline transaminase, the incidence of transaminase increase during treatment was not statistically different between agomelatine-and placebo-treated patients (Table 4) . These results suggest that the presence of a baseline elevation of transaminases, probably related to NAFLD, is not an additive risk of agomelatine-related transaminase increase.
To distinguish between NAFLD and a more likely druginduced liver injury in patients with a transaminase increase, we assumed that an increase of transaminases higher than 5 or 10 9 ULN during treatment was more likely related to agomelatine than to the fluctuation of transaminases observed in NAFLD. We therefore compared the risk of a transaminase increase [5 and 10 9 ULN between patients with a normal and those with an increased baseline level of transaminases (Table 5) . Again, there was no additive effect on the risk of ALT with transaminases [5 or 10 9 ULN evident during agomelatine treatment in patients with an increased baseline level of ALT or AST compared with patients without an increase of baseline level of transminases (for 5 9 ULN: 1.34 vs. 0.78 %; for 10 9 ULN: 0.15 vs. 0.27 %) (Table 5) .
Overall, these analyses suggest that a baseline elevation of transaminases, usually related to NAFLD, is not a risk for agomelatine-induced liver injury.
Discussion
This review of cases of agomelatine-induced hepatotoxicity, as defined by a serum transaminase increase [3 9 ULN, in phase II and III clinical trials shows that the incidence of transaminase increase was low and dose dependent, being 2.5 % at a dose of 50 mg/day versus 1.3 % at 25 mg/day. The majority of increases in serum transaminase occurred within the first 3 months of treatment, and in particular between the fourth and the twelfth weeks after the first intake of agomelatine. Antidepressant-induced liver injury remains a rare event [32] . In a retrospective analysis of duloxetine safety in 23,983 subjects, an increase of ALT was observed in 13 % of patients, 12.7 % (1.7 % of total) of whom had a value [3 9 ULN [33] . A venlafaxine safety study that included 3000 patients showed an incidence of elevated transaminase levels ([3 9 ULN) of 0.4 % [34] . Of note, in these studies, as well as the present analysis, the increase of transaminase was not necessarily related to the drug itself, but may be due to many other causes including alcohol misuse, fatty liver disease viral hepatitis, etc.
We have tried to identify risk factors for transaminase increase in agomelatine-treated patients. Female sex [35, 36] and older age [37] are usually considered as risk factors for drug-induced liver injury; however, we did not find such associations for agomelatine. We found that a baseline serum transaminase level greater than the ULN was associated with an increased risk of observing a serum transaminase [3 9 ULN in both agomelatine-and placebo-treated patients. These data were confounded by the fact that patients taking placebo were treated and monitored for 100 days with an average of 1.8 (±0.9) tests per patient, whereas those taking agomelatine were treated for 160 days with an average of 3.1 (±3.5) tests per patient, and an increased frequency of transaminase measurement is known to be associated with an increased incidence of transaminase elevation in placebo-treated patients [38] . NAFLD is the liver manifestation of the metabolic syndrome [39] . NAFLD is therefore associated with overweight, insulin resistance, diabetes and dyslipidaemia. NAFLD may progress from pure steatosis (fatty liver) to steatohepatitis, fibrosis and cirrhosis [39] . The prevalence , elevated triglycerides (medical history or C1.6 mmol/L), elevated cholesterol (medical history or C8 mmol/L), elevated blood pressure (medical history, systolic blood pressure C130 mmHg or diastolic blood pressure C85 mmHg), elevated blood glucose (medical history or C6.1 mmol/L) of NAFLD is high, about 23 % of the general population, and increases to 74 % among obese individuals [39] . Serum transaminase in patients with NAFLD can vary and may be as high as 8-10 9 ULN, but in most patients levels vary from to 1 to 4 9 ULN. Our patients exhibited a relatively high prevalence of either being overweight (*31 %) or obese (*22 %) and *9 % had an elevated baseline serum transaminase, consistent with a high prevalence of NAFLD. Patients with NAFLD frequently exhibit marked variations in serum transaminase. Thus, it is to be expected that if you treat patients with NAFLD with any drug, some will show an increase in transaminase by chance and unrelated to the study medication. Our results show an increased risk of developing an increase in transaminase[3 9 ULN in patients with probable NAFLD with both agomelatine or placebo; however, the number of placebo cases is relatively small, making an accurate assessment impossible. Therefore, in other analyses we considered that an elevation of transaminases higher than 5 or 10 9 ULN was more likely to be related to agomelatine rather than to fluctuation in NAFLD. In these analyses, a baseline increase of transaminase was not a risk factor for an agomelatine-associated transaminase increase. Thus, in our view, although the data are clear, i.e. if you have elevated liver enzymes at the start of treatment you are more likely to show an increase in serum transaminase [3 9 ULN, we do not believe that NAFLD is an actual risk factor for agomelatine hepatotoxicity.
We observed a dose-dependent risk of transaminase increase, the pooled incidence of transaminase increase being 1.3 and 2.5 % for a daily dose of 25 and 50 mg of agomelatine, respectively. Idiosyncratic hepatotoxicity is classically known to occur without obvious dose dependency and in an unpredictable fashion [40] . Nevertheless, 50 mg/day of drug intake has indeed been suggested to be a threshold of an increased risk of transaminase [41] . No cases of severe liver injury, defined by the occurrence of coagulopathy or any degree of encephalopathy or jaundice, acute liver failure or fatal outcome were observed. Of note, all of the patients with available follow-up data recovered or were recovering. The most specific predictor found to date of a drug's potential for severe hepatotoxicity is the occurrence of a small number of cases of hepatocellular injury accompanied by increased serum total bilirubin (Hy's law [42] ). No cases of Hy's law have been observed in agomelatine phase II and III studies. Another signal is the presence of an increase of transaminase [10 9 ULN. In the present study, 0.2 % of patients with increased transaminases classified as ''possibly'' or ''probably'' related to the treatment displayed such an increase. Among them, all recovered, including one who recovered despite continuation of agomelatine.
One striking observation of this study was that many agomelatine-treated patients recovered from increased transaminases despite continuation of treatment. The phenomenon of transaminase normalisation despite continuation of a treatment has been called adaptation [43] ; it involves genes of drug-metabolising enzymes and transporters. Many elevations of ALT during intake of potentially hepatotoxic drugs may resolve with continued therapy. This adaptation has been clearly demonstrated with isoniazid (reviewed by Saukkonen et al. [44] ). In case of adaptation, patients may exhibit a very high increase of ALT that can resolve completely despite maintenance of [45] . Another possibility is that patients who are unable to develop adaptation are those that tend to develop severe liver injury or even acute liver failure. In line with this hypothesis is that the ALT elevation observed in both patients with and without adaptation occurred in the majority of patients during the first 12 weeks of treatment. It is of note that it is unlikely that a transient elevation of transaminases will have any long-term health consequences if adaptation occurs [45] . There are clear limitations to the present study, the main one being the well-known low ability of clinical trials to evaluate the association between a treatment and liver injury as this adverse event is rare. Clinical trials are of short duration and may exclude patients with pre-existing potential risk factors for liver injury. In addition, the number of patients taking placebo was low. Therefore, the number of patients may be too low to clearly identify independent risk factors, if any, for transaminase increase. We also have not studied other possible risk factors such as co-administration of other drugs, smoking, oral contraception or chronic viral hepatitis. The experts of the agomelatine LSC have reviewed, in addition to the present cases from clinical trials, 390 spontaneous notifications of suspected agomelatine-induced liver injury, many of which were difficult to assess as data were scarce. However, among these cases representing an estimated patient exposure of 13,277,836 patient-months, two cases have been associated with acute liver failure that was assessed as being probably related to agomelatine: in one case, the patient recovered after withdrawal of agomelatine and irbesartan (the other suspected drug for liver failure) (unpublished case); in the other case, the outcome was favourable after a liver transplantation [46] . Of note, there was no follow-up of liver enzymes during agomelatine treatment in this case.
The comparison of liver toxicity between antidepressants is difficult: data are scarce and no comparative trial focusing on this specific aim has been published. Cases of fulminant hepatic failure leading to liver transplantation or death have been reported for other antidepressants, including phenelzine, imipramine, amitriptyline, venlafaxine, duloxetine, sertraline, bupropion and trazodone (see the review by Voican et al. [32] ). Current data suggest that all antidepressants may be associated with a risk of hepatotoxicity. However, the number of reported cases of drug-induced liver injury is inevitably higher for the most frequently used antidepressants, which may tend to indicate, falsely, a higher hepatotoxicity rate. By contrast, is impossible to precisely report the prevalence and severity of antidepressant-induced liver injury [47] . Nevertheless, it has been suggested that the incidence of antidepressant-induced liver toxicity requiring hospitalisation is 1.28-4 cases per 100,000 patient-years, except for nefazodone, for which the incidence can be estimated to be 29 cases per 100,000 patient-years [48, 49] .
Conclusion
In phase II and III trials, agomelatine is associated with a significant but relatively low risk of elevated serum transaminase [3 9 ULN, which may be increased in patients with fatty liver disease. It has been suggested that there is no advantage of increasing the daily dose of agomelatine from 25 to 50 mg on depressive symptoms [50] . As we found a dose dependence for agomelatineinduced transaminase increase, we also recommend the use of a daily dose of 25 mg rather than 50 mg daily. No severe hepatic events were detected. In clinical practice, the regular monitoring of liver function tests is mandatory to identify patients with agomelatine-related hepatotoxicity. A baseline test of transaminases, prior to the first intake of agomelatine, will identify patients with underlying liver disease. Such a test will also allow retrospective identification of patients with an agomelatinerelated liver enzyme increase. Overall, the liver profile of agomelatine seems to be safe when serum transaminases are monitored.
Authorship statement GP, PC, DV, DG and KM analysed all of the suspected cases of liver injury. GP wrote the manuscript. PC, DV, DG, BS and KM corrected the manuscript. BS and CB performed the statistical analyses.
Compliance with Ethical Standards
Funding This work was supported by Servier Pharmaceuticals.
Conflict of interest GP, PC, DV, DG and KM belong to the liver safety committee and received fees from Servier Pharmaceuticals. GP has also received travel funds from Janssen, Abbvie and Gilead, consulting fees from Bayer, Biocodex and Gilead, and royalties from Elsevier-Masson, John Libbey Eurotext and Solar. PC has also received fees from Abbvie, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Pfizer, Roche, Servier and Vifor. PC is an inventor of a patent application owned by his academic institution and licensed to ILTOO Pharma, a biotechnology company developing low-dose interleukin-2 in autoimmune diseases, in which he holds shares. DV has also received consulting fees from Sequana Medical. DG has also received consulting fees from Abbvie, Roche, MSD, Gilead, BMS, Janssen and Alios. BS and CB have received salaries from Servier.
